With better risk stratification, clinicians may be able to optimize medical management of patients with chronic HBV who don’t ...

Liver cancer is the fastest rising cancer killer in Britain and below a nurse revealed the four symtoms she experienced ...

Worldwide, hepatitis B virus is the major risk factor for hepatocellular carcinoma (HCC), owing to its high prevalence in the developing world. Hepatitis B virus vaccination programs have and will ...

Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

CURE spoke with an expert about the potential positive effects of radiation therapy for patients with hepatocellular carcinoma.

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer ...

However, the contribution of FA metabolism reprogramming to the heterogeneity of hepatocellular carcinoma (HCC) has not been established. This article describes how bioinformatics analysis using ...

The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, ...

Evan Seigerman, an analyst from BMO Capital, has initiated a new Buy rating on Replimune Group (REPL).Stay Ahead of the Market:Discover ...

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...